A Phase 1, Multicenter, Open-label, Dose-escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Cvx-241, A Selective Angiopoietin-2 And Vascular Endothelial Growth Factor Binding, Anti-angiogenic Covx-body, In Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2015
At a glance
- Drugs PF 5057459 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 15 Jan 2014 Planned End Date changed from 1 Dec 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov record.
- 15 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 05 Apr 2013 Planned end date changed from 1 Mar 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.